CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CORT$75.03+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
| Common Stock · AdditionalPaid-inCapital · Treasury Stock · AccumulatedOtherComprehensive(Loss) Income · Retained Earnings · TotalStockholders’ Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at December 31, 2022 | 107,835 | $131 | $662,342 | $(456,148) | $(869) | $296,386 | $501,842 |
| Issuance of common stock under incentive award plan | 3,383 | 2 | 29,126 | — | — | — | 29,128 |
| Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises | (1,203) | — | — | (32,424) | — | — | (32,424) |
| Repurchase of common stock in connection with Tender Offer | (6,610) | — | — | (145,428) | — | — | (145,428) |
| Excise tax related to net share repurchases | — | — | — | (1,078) | — | — | (1,078) |
| Stock-based compensation | — | — | 45,977 | — | — | — | 45,977 |
| Vesting of RSAs in connection with ESPP | — | — | 1,070 | — | — | — | 1,070 |
| Other comprehensive income, net of tax | — | — | — | — | 1,478 | — | 1,478 |
| Net income | — | — | — | — | — | 106,140 | 106,140 |
| Balance at December 31, 2023 | 103,405 | 133 | 738,515 | (635,078) | 609 | 402,526 | 506,705 |
| Issuance of common stock under incentive award plan | 3,332 | 3 | 30,810 | — | — | — | 30,813 |
| Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock | (1,138) | — | 2,032 | (45,528) | — | — | (43,496) |
| Repurchase of common stock in connection with Stock Repurchase Program | (486) | — | — | (15,664) | — | — | (15,664) |
| Excise tax related to net share repurchases | — | — | — | 97 | — | — | 97 |
| Stock-based compensation | — | — | 55,710 | — | — | — | 55,710 |
| Vesting of RSAs in connection with ESPP | — | — | 5,041 | — | — | — | 5,041 |
| Other comprehensive loss, net of tax | — | — | — | — | (826) | — | (826) |
| Net income | — | — | — | — | — | 141,209 | 141,209 |
| Balance at December 31, 2024 | 105,113 | 136 | 832,108 | (696,173) | (217) | 543,735 | 679,589 |
| Issuance of common stock under incentive award plan | 4,765 | 4 | 50,043 | — | — | — | 50,047 |
| Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock | (1,320) | — | — | (97,498) | — | — | (97,498) |
| Repurchase of common stock in connection with Stock Repurchase Program | (2,592) | — | — | (172,915) | — | — | (172,915) |
| Stock-based compensation | — | — | 76,508 | — | — | — | 76,508 |
| Vesting of RSAs in connection with ESPP | — | — | 9,941 | — | — | — | 9,941 |
| Other comprehensive income, net of tax | — | — | — | — | 2,481 | — | 2,481 |
| Net income | — | — | — | — | — | 99,652 | 99,652 |
| Balance at December 31, 2025 | 105,966 | $140 | $968,600 | $(966,586) | $2,264 | $643,387 | $647,805 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.